Axatilimab Produces Significant Response in Patients with Fatal Post-Transplant Complication
July 25th 2023Co-developers Incyte and Syndax will submit a biologics license application to the FDA at the end of 2023 based on the results of a phase 2 trial among adult and pediatric patients with chronic graft-versus-host disease.
Read More
As Chemotherapy Drug Shortage Continues, Unimaginable Decisions and Lacking Accountability Reign
July 24th 2023Treatment providers have been forced to adapt and make potentially life-altering decisions for patients due to persistent chemotherapy drug shortages, all while solutions from the FDA and drug manufacturers remain scant.
Read More
Anti-Amyloid Monoclonal Antibody Drugs Continue to Show Promise Treating Alzheimer Disease
July 24th 2023New anti-amyloid monoclonal antibody drugs for Alzheimer disease have produced encouraging results in targeting the accumulation of amyloid beta plaques; however, questions remain regarding the risk-benefit profile and cost implications.
Read More
Mode of Cell Cycle Dysregulation in Cancer Formation Affects Disease Characteristics
July 21st 2023Previous research has determined the role of dysregulation in the evolution of cancers but lacked investigation of the ability of these mutations to predict different forms and aggressiveness of cancer.
Read More